• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB 0.00% 0.9¢

PATRYS LIMITED

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PAB 24/04/24 85 28K
24/04/24 Last post  gassed Comments Created with Sketch.  85  Views Created with Sketch.  28K 
PAB 09/04/24 6 2.2K
09/04/24 Last post  salty74 Comments Created with Sketch.  6  Views Created with Sketch.  2.2K 
PAB
M & A Activities
02/04/24 1 495
02/04/24 Last post  Outgoing123 Comments Created with Sketch.  1  Views Created with Sketch.  495 
PAB 22/03/24 0 361
22/03/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  361 
PAB 22/03/24 0 239
22/03/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  239 
PAB 01/03/24 10 4.0K
01/03/24 Last post  salty74 Comments Created with Sketch.  10  Views Created with Sketch.  4.0K 
PAB
2024 An Eventful Year
2
29/02/24 61 23K
29/02/24 Last post  Lumpster Comments Created with Sketch.  61  Views Created with Sketch.  23K 
PAB 28/01/24 10 4.1K
28/01/24 Last post  Thejerry01 Comments Created with Sketch.  10  Views Created with Sketch.  4.1K 

See All Discussions arrow Created with Sketch.

Timeline

Positive preclinical data for deoxymabs in vasculitis
09 Apr 09:31
 
Change of Director's Interest Notice
22 Mar 09:53
 
Notification of cessation of securities - PAB
22 Mar 09:48
 
Presentation to highlight broader potential of Deoxymabs
04 Mar 10:06
 
Appendix 4D - Half Year Accounts - 31 December 2023
23 Feb 14:51
 
Appendix 4C - Quarterly - 31 December 2023
23 Jan 09:52
 
View More arrow Created with Sketch.
(20min delay)
Last
0.9¢
Change
0.000(0.00%)
Mkt cap ! $18.51M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $4.102K 455.7K

Buyers (Bids)

No. Vol. Price($)
12 2423758 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 1557178 2
View Market Depth
Last trade - 13.26pm 25/04/2024 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.